Bottom line
GTHRX vs QAAGZX: the short answer
GTHRX (INVESCO Health Care Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) are both mutual funds.
But QAAGZX is far broader, holding 277 positions to 82 for GTHRX, so beyond the top names it adds exposure GTHRX doesn't have.
QAAGZX is cheaper at 0.86% vs 1.32% — a difference of $46 a year per $10,000 invested.
Over five years, QAAGZX returned +4.1% a year vs +3.5% for GTHRX.
Updated Nov 19, 2026
GTHRX vs QAAGZX side by side
| GTHRX | QAAGZX | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Invesco | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.32% | 0.86% |
| Annual cost per $10k | $132 | $86 |
| 10-yr cost on $10k (prospectus) | $1,590 | $1,061 |
| Max front load | 0% | None |
| 12b-1 fee | 0.5% | 0% |
| 1-yr return | +15.2% | +18.1% |
| 5-yr return (annualized) | +3.5% | +4.1% |
| 10-yr return (annualized) | +6.1% | +9.0% |
| Best quarter | +19.6% | +23.4% |
| Worst quarter | −16.5% | −15.8% |
| Net assets (fund) | $1.2B | $751.7M |
| Number of holdings | 82 | 277 |
| Portfolio turnover | 59% | 65% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | GTHRX | QAAGZX | Difference |
|---|---|---|---|
| 2024 | +4.0% | +1.7% | +2.3% |
| 2023 | +3.1% | +3.0% | +0.1% |
| 2022 | −13.5% | −12.5% | −1.1% |
| 2021 | +12.2% | +13.1% | −0.9% |
| 2020 | +14.5% | +29.6% | −15.2% |
| 2019 | +32.0% | +29.0% | +3.1% |
| 2018 | +0.5% | +1.1% | −0.7% |
| 2017 | +15.5% | +27.6% | −12.1% |
| 2016 | −11.7% | −10.5% | −1.2% |
Source: Fund prospectus bar charts
Holdings overlap
11 of GTHRX's top 25 holdings also appear in QAAGZX's top 25.
| Holding | GTHRX | QAAGZX |
|---|---|---|
| Eli Lilly and Co. | 10.59% | 14.06% |
| Johnson & Johnson | 6.76% | 6.64% |
| UnitedHealth Group Inc. | 6.17% | 5.88% |
| Merck & Co., Inc. | 4.59% | 4.00% |
| AbbVie Inc. | 4.03% | 5.12% |
| Gilead Sciences, Inc. | 3.63% | 2.79% |
| CVS Health Corp. | 2.52% | 0.93% |
| Cardinal Health, Inc. | 2.10% | 1.04% |
| Guardant Health, Inc. | 2.04% | 1.22% |
| Vertex Pharmaceuticals Inc. | 2.01% | 2.26% |
| Thermo Fisher Scientific Inc. | 1.55% | 2.53% |
Source: SEC Form N-PORT
GTHRX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between GTHRX and QAAGZX?
Which is cheaper, GTHRX or QAAGZX?
Should I own both GTHRX and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.